CPA alone has been found to suppress
ovulation in 3 of 5 women at a dose of 0.5 mg/day and in 5 of 5 women at a dose of 1 mg/day.[6][7][8][9][10][11] Ovulation inhibition with Femilar occurred in 94.4% of 108 women during the third treatment cycle in one study and in almost 100% of 26 women over 12 treatment cycles in another study (except for one woman who ovulated during her first treatment cycle).[5][12][1]
^
abcHirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P (October 1988). "New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women". Maturitas. 10 (3): 201–213.
doi:
10.1016/0378-5122(88)90023-0.
PMID2972897.
^
abHusmann F (1997). "Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement". Women's Health and Menopause. Medical Science Symposia Series. Vol. 11. Springer. pp. 257–261.
doi:
10.1007/978-94-011-5560-1_38.
ISBN978-94-010-6343-2.
ISSN0928-9550.
^Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–557.
doi:
10.1016/j.contraception.2011.04.009.
PMID22078182.
^Spona J, Schneider WH, Bieglmayer C, Schroeder R, Pirker R (1979). "Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations". Acta Obstetricia et Gynecologica Scandinavica. Supplement. 88: 7–15.
doi:
10.3109/00016347909157223.
PMID393050.
S2CID30486799.
^Spona J, Huber J, Schmidt JB (July 1986). "[Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]" [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]. Geburtshilfe und Frauenheilkunde (in German). 46 (7): 435–438.
doi:
10.1055/s-2008-1026659.
PMID3093307.
S2CID260156932.
^Spona J, Huber J (1987). "Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate". Gynecologic and Obstetric Investigation. 23 (3): 184–193.
doi:
10.1159/000298860.
PMID2954886.
^Spona J, Huber J, Schmidt JB (1987-12-31). "Ovulation inhibitory effect of SH B 209 AE (Diane-35)—a new antiandrogen-estrogen combination". In Schindler AE (ed.). Antiandrogen-Estrogen Therapy for Signs of Androgenization. Berlin, Boston: De Gruyter. pp. 51–58.
doi:
10.1515/9783110866902-006.
ISBN9783110866902.
CPA alone has been found to suppress
ovulation in 3 of 5 women at a dose of 0.5 mg/day and in 5 of 5 women at a dose of 1 mg/day.[6][7][8][9][10][11] Ovulation inhibition with Femilar occurred in 94.4% of 108 women during the third treatment cycle in one study and in almost 100% of 26 women over 12 treatment cycles in another study (except for one woman who ovulated during her first treatment cycle).[5][12][1]
^
abcHirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P (October 1988). "New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women". Maturitas. 10 (3): 201–213.
doi:
10.1016/0378-5122(88)90023-0.
PMID2972897.
^
abHusmann F (1997). "Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement". Women's Health and Menopause. Medical Science Symposia Series. Vol. 11. Springer. pp. 257–261.
doi:
10.1007/978-94-011-5560-1_38.
ISBN978-94-010-6343-2.
ISSN0928-9550.
^Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–557.
doi:
10.1016/j.contraception.2011.04.009.
PMID22078182.
^Spona J, Schneider WH, Bieglmayer C, Schroeder R, Pirker R (1979). "Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations". Acta Obstetricia et Gynecologica Scandinavica. Supplement. 88: 7–15.
doi:
10.3109/00016347909157223.
PMID393050.
S2CID30486799.
^Spona J, Huber J, Schmidt JB (July 1986). "[Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]" [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]. Geburtshilfe und Frauenheilkunde (in German). 46 (7): 435–438.
doi:
10.1055/s-2008-1026659.
PMID3093307.
S2CID260156932.
^Spona J, Huber J (1987). "Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate". Gynecologic and Obstetric Investigation. 23 (3): 184–193.
doi:
10.1159/000298860.
PMID2954886.
^Spona J, Huber J, Schmidt JB (1987-12-31). "Ovulation inhibitory effect of SH B 209 AE (Diane-35)—a new antiandrogen-estrogen combination". In Schindler AE (ed.). Antiandrogen-Estrogen Therapy for Signs of Androgenization. Berlin, Boston: De Gruyter. pp. 51–58.
doi:
10.1515/9783110866902-006.
ISBN9783110866902.